Evotec and Dewpoint Therapeutics enter strategic partnership

Betsy Goodfellow | November 7, 2023 | News story | Research and Development Dewpoint Therapeutics, Evotec, Oncology, R&D, oncology 

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s oncology pipeline programmes of condensate modifying therapeutics (c-mods) to Investigational New Drug Applications (INDs) through the use of Evotec’s fully integrated data-driven platform (INDiGO).

The partnership is intended to bring together Dewpoint’s advanced oncology pipeline programmes with Evotec’s ability to de-risk and accelerate pre-clinical development candidates to first-in-human clinical trials.

Under terms of the agreement, Evotec will facilitate the development of Dewpoint’s oncology assets using Evotec’s INDiGO platform to accelerate the path to clinical testing. This agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec depending on the success of the overall programmes.

Advertisement

Dr Matthias Evers, chief business officer of Evotec, commented: “We are excited to enter this strategic development partnership with Dewpoint. Its innovative approach is based on a holistic understanding, which can significantly expand the target space across indications. By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership. We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”

Betsy Goodfellow

Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

drug-trials

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland

Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

The Gateway to Local Adoption Series

Latest content